A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models

por Sun, Kaiming, Mikule, Keith, Wang, Zebin, Poon, Grace, Vaidyanathan, Aparajitha, Smith, Gillian, Zhang, Zhi-Yi, Hanke, Jeffrey, Ramaswamy, Sridhar, Wang, Jing
Publicado 2018

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

por Wang, Zebin, Sun, Kaiming, Xiao, Yonghong, Feng, Bin, Mikule, Keith, Ma, XiaoYan, Feng, Ningping, Vellano, Christopher P., Federico, Lorenzo, Marszalek, Joseph R., Mills, Gordon B., Hanke, Jeffrey, Ramaswamy, Sridhar, Wang, Jing
Publicado 2019

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

por Singh, Sanjaya, Kroe-Barrett, Rachel R, Canada, Keith A, Zhu, Xiang, Sepulveda, Eliud, Wu, Helen, He, Yaqin, Raymond, Ernest L, Ahlberg, Jennifer, Frego, Lee E, Amodeo, Laura M, Catron, Katrina M, Presky, David H, Hanke, Jeffrey H
Publicado 2015